Rafinlar 50 mg Capsule
$320.72
$250.16
Rafinlar 50 mg capsules are a targeted therapy specifically designed for adults battling unresectable or metastatic melanoma characterized by a BRAF V600 mutation, whether used alone or in conjunction with trametinib. This innovative medication is also approved for the adjuvant treatment of patients with Stage III melanoma harboring the same genetic alteration. Furthermore, Rafinlar is indicated for advanced non-small cell lung cancer in adults with a confirmed BRAF V600 mutation, showcasing its versatility in treating various malignancies linked to this mutation. By inhibiting the abnormal BRAF protein, Rafinlar helps to slow down cancer cell growth and spread, offering hope for improved outcomes. Patients should be aware of potential side effects, including skin rashes and elevated liver enzymes, necessitating regular monitoring by healthcare professionals. As a vital component of personalized cancer therapy, Rafinlar empowers clinicians to tailor treatment strategies effectively. Always consult a healthcare provider before starting Rafinlar to ensure it aligns with individual health needs and conditions.
Quantity
Active Pharmaceutical Ingredient
Uses
• Rafinlar 50 mg capsule is primarily used in the treatment of melanoma, a type of skin cancer. It is effective for patients with specific genetic mutations that drive tumor growth. By targeting these mutations, Rafinlar 50 mg capsule helps inhibit the cancer cells' ability to proliferate. This targeted approach can lead to improved outcomes for patients facing this challenging condition.
• In addition to melanoma, Rafinlar 50 mg capsule is also indicated for the adjuvant treatment of melanoma following surgical removal of the tumor. This means it is used to reduce the risk of cancer recurrence after surgery. The administration of Rafinlar 50 mg capsule in this context aims to eliminate any remaining cancer cells that could lead to relapse. It plays a crucial role in enhancing long-term survival prospects for patients.
• Rafinlar 50 mg capsule is also utilized in the treatment of non-small cell lung cancer (NSCLC). This medication is prescribed for patients with specific genetic alterations that are responsive to the treatment. By using Rafinlar 50 mg capsule, healthcare providers can offer a targeted therapy option that may lead to better management of the disease. Its effectiveness in NSCLC demonstrates its versatility in oncology.
• The use of Rafinlar 50 mg capsule extends to patients with advanced melanoma who have previously received other treatments. It serves as a second-line therapy option for those who may not have responded well to initial treatments. This flexibility allows oncologists to tailor treatment plans based on individual patient needs. Rafinlar 50 mg capsule thus provides an important alternative for managing advanced stages of melanoma effectively.
Benefits
Skin cancer (Melanoma): melanoma is a type of skin cancer that develops in melanocytes, the cells that produce the pigment called melanin. Melanin is the pigment that gives the skin its color. Malignant melanoma is the most deadly and aggressive kind of skin cancer. Rafinlar 50 mg Capsule sticks to the genetic code, called DNA, of the cancer cells and kills them. It also prevents their growth and further spread, which help treat cancer. Adjuvant treatment of melanoma: Rafinlar 50 mg Capsule used in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation. Non-small cell lung cancer (NSCLC): Non-small cell lung cancer is one of the major kinds of lung cancer, and it affects both smokers and non-smokers. Rafinlar 50 mg Capsule helps treat non-small cell lung cancer and may be given alone or in combination with other medicines. It is a potent and very toxic medicine, and you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol while having this treatment and drink plenty of water to stay hydrated.
Side Effects
Most adverse effects do not require medical attention and will go away when your body gets used to the medicine. Inform your doctor if any of these symptoms get severe or that bother you for a longer period.
Most Common Side Effects
• Joint and muscle or back pain
• Loss of appetite
• Cough, running nose
• Sore throat
• Hair loss
• Tiredness
• Skin changes ( skin sore, red bump which bleeds or does not heal)
• Fainting
• Dizziness
• weakness
• chills
Common Side Effects
• Fever
• Itching
• Rashes
• Nausea
• DiarrhoeaDecreased urination
• Polyurea ( frequent urination)
• Increased thirst
• Red swollen eyelids
• Photosensitivity ( sensitive to light)
• Chest pain
• Breathing difficulty
How To Use
Rafinlar 50 mg Capsule can be taken 1 hour before a meal or after 2 hours after a meal daily as directed by the doctor. Your doctor will decide the dose and frequency as per the severity of your disease and several other factors. Don't miss a regular dose of medicine. If you forget to take it, take it as early as you remember.
Safety Advice
• Alcohol: It is generally not recommended to drink alcohol while taking Rafinlar 50 mg Capsule. It may increase the risk of liver damage. it is best to avoid alcohol or limit your alcohol consumption while taking any medication.
• Kidney: No dose adjustment is required for patients with mild or moderate renal impairment. There are no clinical data on subjects with severe renal impairment and the potential need for dose adjustment cannot be determined. Rafinlar 50 mg Capsule should be used with caution in patients with severe renal impairment when administered as monotherapy or in combination with trametinib.
• Breastfeeding: It is not known whether the ingredients of Rafinlar 50 mg Capsule can pass into breast milk. If you are breastfeeding, or planning to breastfeed, you must tell your doctor. You and your doctor will decide if you will take this medicine or breastfeed.
• Liver: No dose adjustment is required for patients with mild hepatic impairment. There are no clinical data on subjects with moderate to severe hepatic impairment and the potential need for dose adjustment cannot be determined. Rafinlar 50 mg Capsule should be used with caution in patients with moderate or severe hepatic impairment when administered as monotherapy or in combination with trametinib.
• Pregnancy: Use of Rafinlar 50 mg may be unsafe during pregnancy as animal studies indicate that it may harm the developing foetus. However, if you are pregnant or planning to become pregnant, it is important to talk to your doctor about the potential risks and benefits of taking Rafinlar 50 mg Capsule during pregnancy. Your doctor will be able to help you make the best decision for you and your baby's health.
• Driving: Rafinlar 50 mg Capsule can have side effects that may affect your ability to drive or use machines. Avoid driving or using machines if you have problems with your vision or if you feel tired or weak, or if your energy levels are low.